Primary Site >> Colorectal Cancer
Gene >> CD55
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. PMID: 1384641 |
Ref: Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer. PMID: 7544751 |
Ref: Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). PMID: 8686736 |
Ref: The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. PMID: 9808413 |
Ref: Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours. PMID: 10211099 |
Ref: 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses. PMID: 10585589 Ref: A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. PMID: 10690519 Ref: A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions. PMID: 11069077 |
Ref: CD55 is over-expressed in the tumour environment. PMID: 11139317 Ref: Polymorphic expression of decay-accelerating factor in human colorectal cancer. PMID: 11207899 Ref: Glycophosphatidylinositol-anchored protein deficiency as a marker of mutator phenotypes in cancer. PMID: 11212264 Ref: Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. PMID: 11384090 Ref: Epidermal growth factor induces expression of decay-accelerating factor in human colonic cancer cells via the mitogen-activated protein kinase pathway. PMID: 11528371 Ref: Immunization against tumor cell surface complement-regulatory proteins. PMID: 11757799 Ref: Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer. PMID: 12086907 |
Ref: Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. PMID: 11754353 Ref: Advances in the development of a reliable assay for the measurement of stool decay-accelerating factor in the detection of colorectal cancer. PMID: 12458732 |
Ref: Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. PMID: 12811528 Ref: Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer. PMID: 14638362 Ref: Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor. PMID: 14647034 |
Ref: Difference in Ulex europaeus agglutinin I-binding activity of decay-accelerating factor detected in the stools of patients with colorectal cancer and ulcerative colitis. PMID: 15007307 Ref: Loss of CD55 is associated with aggressive breast tumors. PMID: 15102687 |
Ref: Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer. PMID: 15520008 |
Ref: Dexamethasone modifies the susceptibility to serum cytotoxicity and increases the metastatic efficiency of a colon carcinoma cell line. PMID: 16380115 Ref: Multiplex detection of surface molecules on colorectal cancers. PMID: 16485257 Ref: Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces beta-glucan-dependent CR3-dependent cellular cytotoxicity. PMID: 16525993 Ref: Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. PMID: 16533428 Ref: A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. PMID: 17121873 |
Ref: Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors. PMID: 17234541 |
Ref: High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. PMID: 21526778 |
Ref: Characterization of novel CD55 isoforms expression in normal and neoplastic tissues. PMID: 23692281 |
Ref: A novel indole compound, AWT-489, inhibits prostaglandin D2-induced CD55 expression by acting on DP prostanoid receptors as an antagonist in LS174T human colon cancer cells. PMID: 24239863 Ref: CD55 limits sensitivity to complement-dependent cytolysis triggered by heterologous expression of alpha-gal xenoantigen in colon tumor cells. PMID: 24763553 Ref: Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer. PMID: 24978917 |
Ref: Silencing of CD59 enhanced the sensitivity of HT29 cells to 5-Fluorouracil and Oxaliplatin. PMID: 25444672 |
Ref: Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples. PMID: 27086589 |
Ref: Combination of oncolytic adenovirus and luteolin exerts synergistic antitumor effects in colorectal cancer cells and a mouse model. PMID: 29039580 |